Ciltacabtagene autoleucel vs Pamlectabart tismanitin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
Ciltacabtagene autoleucel
Marketed by Johnson & Johnson under a licence from Legend Biotech Corporation
NCT04181827 · Phase 3 · active, not recruiting
This was a large randomized phase 3 trial against active standard therapy, and its primary endpoint, progression-free survival, clearly favoured cilta-cel (hazard ratio 0.26, P<0.001). However, it was open-label: patients and doctors knew which treatment was given, so the evidence is rated below the top level.
Next expected readout: February 2027 · NCT04133636 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) (From randomization (Day 1) to either progressive disease or death, whichever occurred first (up to 3.9 years)): Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023). (met)
Result source: NCT04181827
Pamlectabart tismanitin
Developed by Heidelberg Pharma AG and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2028 · NCT04879043 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ciltacabtagene autoleucel | Pamlectabart tismanitin |
|---|---|---|
| PFS, median | —Trial running · NCT05257083 | —Not reported |
| OS, median | 27.0bNCT03548207 | —Not reported |
| ORR | 97.1%bNCT035482072 other results
| —Not reported |
| VGPR or better | 96.6%bNCT035482072 other results
| —Not reported |
| MRD negativity | 100%bNCT035482072 other results
| —Not reported |
PFS, median
- Ciltacabtagene autoleucel
- —Trial running · NCT05257083
- Pamlectabart tismanitin
- —Not reported
OS, median
- Ciltacabtagene autoleucel
- 27.0bNCT03548207
- Pamlectabart tismanitin
- —Not reported
ORR
- Ciltacabtagene autoleucel
- 97.1%bNCT03548207
2 other results
- 57.3% NCT05347485
- 100% NCT03548207
- Pamlectabart tismanitin
- —Not reported
VGPR or better
- Ciltacabtagene autoleucel
- 96.6%bNCT03548207
2 other results
- 94.1% NCT03548207
- 100% NCT03548207
- Pamlectabart tismanitin
- —Not reported
MRD negativity
- Ciltacabtagene autoleucel
- 100%bNCT03548207
2 other results
- 89.7% NCT03548207
- 75% NCT03548207
- Pamlectabart tismanitin
- —Not reported
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Pamlectabart tismanitin: no structured comparison results are available for Multiple Myeloma.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ciltacabtagene autoleucel: 2 of 4 rows · Pamlectabart tismanitin: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ciltacabtagene autoleucel |
|---|---|
| Dropout rate | n/a: no completion milestonea NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more resultsn/a: no completion milestonePhase 1b (US Population) NCT03548207 · Phase 1/2 n/a: no completion milestonePhase 2 (Japan Population) NCT03548207 · Phase 1/2 n/a: no completion milestonePhase 2 (US Population) NCT03548207 · Phase 1/2 n/a: no completion milestone NCT05347485 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more results—Phase 1b (US Population) NCT03548207 · Phase 1/2 —Phase 2 (Japan Population) NCT03548207 · Phase 1/2 —Phase 2 (US Population) NCT03548207 · Phase 1/2 — NCT05347485 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 47.1%a NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more results37.9%Phase 1b (US Population) NCT03548207 · Phase 1/2 11.1%Phase 2 (Japan Population) NCT03548207 · Phase 1/2 61.8%Phase 2 (US Population) NCT03548207 · Phase 1/2 51.2% NCT05347485 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a neutropenia 89.9% cytokine release syndrome 62% thrombocytopenia 54.3% NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more resultsneutropenia 80.5% anaemia 59.8% cytokine release syndrome 57.3% NCT05347485 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ciltacabtagene autoleucel
show 2 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 27 more results
show 27 more results
show 27 more results
+ 5 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ciltacabtagene autoleucel's landscape · Pamlectabart tismanitin's landscape